莫西沙星注射液治疗社区获得性肺炎的临床疗效观察  

The Clinical Curative Effect of Moxifloxacin in the Treatment of Community Acquired Pneumonia

作　　者：王双[1,2] 王燕[3] 陈宝元[1] 陈哲[1] 吴琦[1] 曹洁[1] 董丽霞[1] 

机构地区：[1]天津医科大学总医院呼吸科,天津300052 [2]天津市职工医院,天津300050 [3]天津医科大学总医院肿瘤科,天津300052

出　　处：《继续医学教育》2014年第12期118-120,共3页Continuing Medical Education

摘　　要：目的评价莫西沙星注射液对社区获得性肺炎(CAP)的临床疗效、细菌学疗效及安全性。方法采用区组随机化、开放、阳性药物对照和非对照的试验方法,对48例CAP患者随机分为治疗组(莫西沙星)、对照组(左氧沙星)和非对照开放组(莫西沙星),分别给予莫西沙星注射液和左氧氟沙星注射液进行治疗。结果 CAP治疗组的临床有效率为85.7%,对照组为64.3%;两组间比较无统计学差异(P>0.05)。CAP治疗组的细菌学清除率为83.3%,对照组为85.7%;两组比较无统计学差异(P>0.05)。非对照组临床有效率为100%,细菌清除率为92.3%。不良反应的发生率低,大多为轻度一过性,继续用药或停药后缓解和改善,无严重不良反应事件发生。两组的不良事件发生率经统计学检验无差异(P>0.05)。结论莫西沙星注射液治疗CAP的临床疗效确切,耐受性良好,安全性较高,是治疗CAP的有效药物。Objective Evaluate the clinical efficacy of moxifloxacin injection of community-acquired pneumonia（CAP）, bacteriological efficacy and safety. Methods Using block randomization, open, positive drug test methods of controlled and uncontrolled, 48 patients were randomly divided into treatment group（Moxifloxacin）, control group（levofloxacin） and uncontrolled open group（Moxifloxacin）, injections were given moxifloxacin and levofloxacin injection treatment. Results Effective clinical treatment group was 85.7%, the control group was 64.3%; There was no significant difference between the two groups（P〉0.05）. CAP treatment group the bacteriology of clearance rate was 83.3%, the control group is 85.7%; There was no significant difference between the two groups（P〉0.05）. Effective non-clinical control group was 100%, bacterial clearance rate was 92.3%. Lower respiratory tract infection Low incidence of adverse reactions, mostly mild transient, continue after discontinuation of medication or mitigation and improvement, no serious adverse events occurred. There was no significant difference in the adverse events of the two groups（P〉0.05）. Conclusion The clinical efficacy of moxifloxacin injection in the treatment of CAP precise, well tolerated, high security, is an effective drug for the treatment of CAP.

关 键 词：社区获得性肺炎 莫西沙星注射液 左氧沙星注射液 细菌感染 

分 类 号：R563.1[医药卫生—呼吸系统]